SCHEMBL1099360

SCHEMBL1099360

CC(C)CN(c1sc2ccccc2c1Br)S(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 9/20 0.56
TAS2R14 Q9NYV8 2/20 0.51
TRPM8 Q7Z2W7 5/20 0.49
BCL2L1 Q07817 4/20 0.43
RORC P51449 1/20 0.42
NR1H4 Q96RI1 1/20 0.41
ALOX5 P09917 2/20 0.40
PTGES O14684 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100682 0.89 TRPM8 (0.49) MCL1TAS2R14TRPM8ALOX5PTGES
SCHEMBL1099776 0.88 TRPM8 (0.52) MCL1TAS2R14TRPM8ALOX5PTGES
SCHEMBL1099503 0.86 TRPM8 (0.50) MCL1TAS2R14TRPM8ALOX5PTGES
SCHEMBL1098422 0.85 TRPM8 (0.49) MCL1TAS2R14TRPM8ALOX5PTGES
SCHEMBL1099163 0.84 ALOX5 (0.57) MCL1TAS2R14TRPM8ALOX5PTGES
SCHEMBL1099496 0.83 TRPM8 (0.50) MCL1TAS2R14TRPM8RORCALOX5
SCHEMBL1100684 0.83 ALOX5 (0.57) MCL1TAS2R14TRPM8ALOX5PTGES
SCHEMBL1100559 0.82 ALOX5 (0.59) MCL1TAS2R14TRPM8ALOX5PTGES
SCHEMBL1100757 0.82 TRPM8 (0.53) TAS2R14TRPM8RORCALOX5PTGES
SCHEMBL1100381 0.82 PTGES (0.52) TAS2R14TRPM8ALOX5PTGESMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
CN-101801949-A Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2010-08-11 CN disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MCL1 3803/4885TAS2R14 182/4885TRPM8 1/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MCL1 3803/4885TAS2R14 182/4885TRPM8 1/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MCL1 3803/4885TAS2R14 182/4885TRPM8 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.